{"filing":{"accession_number":"0001193125-26-249790","cik":"0001739410","ticker":"RLYB","company_name":"Rallybio Corp","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"d19106d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526249790/d19106d8k.htm"},"events":[{"id":10419,"run_id":9137,"accession_number":"0001193125-26-249790","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Rallybio Corporation entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics on May 31, 2026, whereby Avenzo will survive as a wholly-owned subsidiary of Rallybio. The transaction represents a material change of control with Avenzo equityholders expected to own approximately 56.6% of the combined company post-closing.","company_name":"Rallybio Corp","ticker":"RLYB","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":6730,"accession_number":"0001193125-26-249790","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Rallybio Corporation entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics on May 31, 2026, whereby Avenzo will survive as a wholly-owned subsidiary of Rallybio. This is a material acquisition/change of control transaction with significant ownership restructuring (Avenzo equityholders expected to own ~56.6% of combined company post-closing) and executive leadership transition, disclosed under Item 1.01 as required for material definitive merger agreements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6732,"accession_number":"0001193125-26-249790","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses a \"Changes in Control of Registrant\" and explicitly incorporates Item 1.01 by reference. Item 1.01 covers material acquisitions and other transactions that result in a change of control. This is a material event affecting ownership and control of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6734,"accession_number":"0001193125-26-249790","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses execution of a Merger Agreement between Rallybio and Avenzo announced via joint press release on June 1, 2026. Although disclosed under Item 7.01 (Other Events) rather than the typical Item 1.01 or 2.01, the substance is clearly a material acquisition/merger event. The announcement of a merger agreement is a transformative corporate event that would materially affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10420,"run_id":9137,"accession_number":"0001193125-26-249790","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Concurrent with the merger, Rallybio is issuing unregistered Avenzo Class A common stock in private placements exempt under Section 4(a)(2) and Regulation D, materially diluting existing shareholder ownership.","company_name":"Rallybio Corp","ticker":"RLYB","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":6731,"accession_number":"0001193125-26-249790","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities in a \"Concurrent Financing\" involving issuance of Avenzo Class A common stock in private placements exempt under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance that would materially affect shareholder ownership and is typically material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10421,"run_id":9137,"accession_number":"0001193125-26-249790","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Rallybio amended employment and separation agreements for named executives Stephen Uden, Jonathan Lieber, and Steven Ryder to modify their change-of-control compensation, benefits, and equity treatment in connection with the merger.","company_name":"Rallybio Corp","ticker":"RLYB","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":6733,"accession_number":"0001193125-26-249790","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on amendments to employment and separation agreements for Stephen Uden, Jonathan Lieber, and Steven Ryder that modify their change-of-control compensation and benefits in connection with a merger. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from a departure or appointment. The materiality is high given the context of a change of control transaction affecting named executives' severance and equity treatment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6730,"accession_number":"0001193125-26-249790","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Rallybio Corporation entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics on May 31, 2026, whereby Avenzo will survive as a wholly-owned subsidiary of Rallybio. This is a material acquisition/change of control transaction with significant ownership restructuring (Avenzo equityholders expected to own ~56.6% of combined company post-closing) and executive leadership transition, disclosed under Item 1.01 as required for material definitive merger agreements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"Rallybio Corp","ticker":"RLYB","filing_date":"2026-06-01"},{"id":6731,"accession_number":"0001193125-26-249790","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities in a \"Concurrent Financing\" involving issuance of Avenzo Class A common stock in private placements exempt under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance that would materially affect shareholder ownership and is typically material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"Rallybio Corp","ticker":"RLYB","filing_date":"2026-06-01"},{"id":6732,"accession_number":"0001193125-26-249790","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses a \"Changes in Control of Registrant\" and explicitly incorporates Item 1.01 by reference. Item 1.01 covers material acquisitions and other transactions that result in a change of control. This is a material event affecting ownership and control of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"Rallybio Corp","ticker":"RLYB","filing_date":"2026-06-01"},{"id":6733,"accession_number":"0001193125-26-249790","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on amendments to employment and separation agreements for Stephen Uden, Jonathan Lieber, and Steven Ryder that modify their change-of-control compensation and benefits in connection with a merger. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from a departure or appointment. The materiality is high given the context of a change of control transaction affecting named executives' severance and equity treatment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"Rallybio Corp","ticker":"RLYB","filing_date":"2026-06-01"},{"id":6734,"accession_number":"0001193125-26-249790","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses execution of a Merger Agreement between Rallybio and Avenzo announced via joint press release on June 1, 2026. Although disclosed under Item 7.01 (Other Events) rather than the typical Item 1.01 or 2.01, the substance is clearly a material acquisition/merger event. The announcement of a merger agreement is a transformative corporate event that would materially affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:20:21.498942+00:00","company_name":"Rallybio Corp","ticker":"RLYB","filing_date":"2026-06-01"}]}